{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.8","upperLimit":"6.9","value":"3.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Time to progression (TTP) is defined to be the length of time from study registration to a) date of disease progression as defined by section 11.0 of the protocol, or b) last follow-up. If a patient dies without documentation of disease progression, the patient will be considered to have had a tumor progression at the time of death unless there is sufficient documented evidence to conclude no progression occurred prior to death. Time to progression curves were compared via the log-rank test. Progression is defined as a \\>25% increase in product of perpendicular diameters of contrast enhancement or mass or appearance of new lesions or unequivocal increase in size of contrast enhancement or increase in mass effect as agreed upon independently by primary physician and quality control physicians: appearance of new lesions compared to pretreatment MRI and/or CT scan.","dispersionType":"Full Range","groups":[{"description":"Patients receive 20 mg cytarabine (AraC) SC twice daily and 200 mg WEE1 inhibitor (AZD1775) PO daily on days 1-5 and days 8-12 OR receive only 200 mg WEE inhibitor (AZD1775) PO daily on days 1-5, 8-12, 15-19, and 22-26.","id":"OG000","title":"Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)"}],"paramType":"MEDIAN","populationDescription":"Since only one patient was accrued on one arm, patient confidentiality prevents the reporting of results by arm.","reportingStatus":"POSTED","timeFrame":"Up to 17 months","title":"Time to Progression, Defined as the Time From Registration to the Earliest Date of Documentation of Disease Progression","type":"SECONDARY","unitOfMeasure":"months"}